News and Trends 13 Dec 2022 Poolbeg influenza trial successfully completed Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza. The study showed no further clinical activity is required to complete the objectives of the trial, bringing the recruitment […] December 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 12 Dec 2022 Artificial intelligence: a new era in rare genetic disease diagnosis Despite the onset of the genomics era, rare disease diagnosis remains a challenge. Nostos Genomics’ co-founder, Rocío Acuña Hidalgo, and chief operating officer, Ansgar Lange, shed light on how artificial intelligence (AI) could fill in the gaps. It is estimated that 300 million people worldwide are affected by rare diseases and around 80% of these […] December 12, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 Japanese research offers hope for Fukuyama muscular dystrophy patients Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy in Japan. The disease manifests itself in the form of a severe neuromuscular disorder. One form of FCMD is caused by a genetic abnormality in the fukutin (FKTN) gene. The genetic anomaly blocks the chemical glycosylation of a biologically important […] December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B- and T-ALL). The information was provided at the American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The preclinical data on OSE-127 presented […] December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 Enterome completes patient enrollment for recurrent glioblastoma study Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead OncoMimics candidate, EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer. Enterome is a French clinical stage company developing first-in-class immunomodulatory drugs […] December 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 Studying the global spread of antimicrobial resistance An international research team has provided new information about what drives the global spread of genes responsible for antimicrobial resistance (AMR) in bacteria. The collaborative study, led by researchers at the Quadram Institute and the University of East Anglia in the U.K., brought together experts from France, Canada, Germany and the U.K. and will provide […] December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 Antibody discovery could lead to new therapies to tackle Strep A Researchers at Lund University in Sweden have discovered an antibody with the potential to protect against Strep A infection, as well as a rare form of antibody binding, that leads to an effective immune response against bacteria. The researchers say the discovery could explain why so many group A strep vaccines have failed. The results […] December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 Step Pharma announces promising pre-clinical cancer data Step Pharma has announced encouraging pre-clinical data on its first-in-class, highly selective, orally bioavailable CTPS1 inhibitor, STP938. The data were presented at the 64th American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The data presented by Step Pharma collaborators demonstrates the potential of STP938, a highly selective CTPS1 inhibitor, as a therapeutic […] December 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 New biomaterial can regenerate bones and prevent infections Researchers in Spain have developed a new porous material capable of regenerating bones and preventing infections at the same time. The scientists are from the Bioengineering and Biomaterials Laboratory of Universidad Católica de Valencia (UCV) . Tailor-made for each case using 3D printing, the biotech creations contain a bioactive alginate coating. This coating induces bone regeneration […] December 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Vevo Therapeutics launches with $12M to ‘discover better drugs’ Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, has launched with an oversubscribed and upsized $12 million seed financing round. Wing Venture Capital and General Catalyst co-led the round with participation from Mubadala Capital, AIX Ventures, and Camford […] December 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Siddhartha Mukherjee, assistant professor of Medicine at Columbia University Medical Center in the Department of Medicine and Division […] December 9, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Visiox Pharma announces FDA acceptance of glaucoma new drug application Visiox Pharma, LLC has received notification from the U.S. Food and Drug Administration (FDA) that the agency has completed its filing review and accepted for filing the New Drug Application (NDA) for PDP-716 (0.35% brimonidine tartrate) for the treatment of glaucoma. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date […] December 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email